p53 and p53-regulated genes in bladder cancer

British Journal of Urology

Volumn 82, Issue 5, 1998, Pages 710-720

  Keegan, P E ^a,b   Lunect, J ^b   Neal, D E ^a  

^a Department of Surgery ^*

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bladder cancer; Immunohistochemistry; MDM2; p53; Prognostic markers; Proto oncogenes; Tumour suppressor gene

Indexed keywords

PROTEIN P53;

BLADDER CANCER; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, P53; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA; THROMBOSPONDINS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0031794320     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00822.x     Document Type: Review

References (77)

1. Kastan MB, Zhan Q. el-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-97
2. Rotter V, Aloni-Grinstein R. Schwartz D et al Does wildtype p53 play a role in normal cell differentiation? Semin Cancer Biol 1994: 5: 229-36
3. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994; 5: 221-7
4. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996: 1287: 77-102
5. Lane DP. Cancer. p53, guardian of the genome [news; commentJ. Nature 1992: 358: 15-6
6. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 1995; 17: 501-8
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991: 253: 49-53
8. Lee S, Elenbaas B. Levine A. Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995; 81: 1013-20
9. Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995: 81: 1021-9
10. Velculescu VE. El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996: 42: 858-68
11. Ko LJ. Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-72
12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-55
13. Fakharzadeh SS, Trusko SP. George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo }1991; 10: 1565-9
14. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993: 362: 857-60
15. Jones SN, Roe AE. Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-8
16. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2 -deficient mice by deletion of p53. Nature 1995; 378: 203-6
17. Piette f. Neel H. Maréchal V. Mdm2: keeping p53 under control. Oncogene. 1997: 15: 1001-10
18. Momand J, Zambetti GP. Mdm-2: 'big brother' of p53. J Cd; Biochem 1997; 64: 343-52
19. Chowdary DR, Dermody JJ. Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994; 14: 1997-2003
20. Hansen R, Oren M. p53: from inductive signal to cellular effect. Curr Opin Genet Dev 1997; 7: 46-51
21. Levine AJ. p53. the cellular gatekeeper for growth and division. Cell 1997: 88: 323-31
22. Sherr CJ. Cancer cell cycles. Science 1996: 274: 1672-7
23. Heiin K. Peters G. Tumor suppressors: from genes to function and possible therapies. Trends Genet 1998: 14: 8-9
24. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996; 6: 12-8
25. Naumovski L. Cleary ML. The p53-binding protein 53 bp2 also interacts with Be 12 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996; 16: 3884-92
26. Buckbinder L, Talbott R. Velasco-Miguel S et al. Induction of the growth inhibitor IGF-binding protein 3 by p 5 3. Nature 1995; 377: 646-9
27. Polyak K, Xia Y, Zweier JL. Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-5
28. Finlay CA. Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9
29. Cordon-Cardo C, Dalbagni G. Saez GT et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347-53
30. Abdel-Fattah R. Challen C, Griffiths TRL, Robinson MC, Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998: in press:
31. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? Revisited! [editoriall./Pat/ioJ 1994; 172: 1-4
32. Baas 10, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994: 172: 5-12
33. 3 Sidransky D, Von Eschenbach A. Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. .Science 1991; 252: 706-9
34. Fujimoto K, Yamada Y. Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393-8
35. 5 Messing EM, Catalona W. Urothelial tumours of the urinary tract. In Walsh PC. Retik AB. Vaughan EAJW, eds, Campbell's Urology. 7th ed. Vol. 3. Philadelphia: Saunders, 1997: 2327-410
36. Theodorescu Ü. Editorial comment. J Urol 1998; 159: 791
37. Sarkis AS. Dalbagni G. Cordon-Cardo C et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388-92
38. Sarkis AS, Zhang ZF, Cordon-Cardo C et al. p53 nuclear overexpression and disease progression in Ta bladder carcinoma, bit }Oncol 1993; 3: 355-60
39. Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A. p5 3 expression compared with other prognostic factors in Oms grade-I stage-Ta transitional cell carcinoma of the bladder. Ear Urol 1997; 32: 229-36
40. Serth ). Kuczyk MA. Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201-5
41. Kuczyk MA. Bokemeyer C, Serth J et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Kur }Cancer 1995: 31A: 2243-7
42. Sarkis AS. Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M VAC. J Clin Oncol 1995; 13: 1384-90
43. Wu CS. Pollack A. Czerniak B et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996; 47: 305-10
44. Jahnson S. Risberg B. Karlsson MG. Westman G. Bergstrom R, Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 1995; 28: 135-42
45. Esrig D. Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-64
46. Lacombe L, Dalbagni G. Zhang ZF et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus CalmetteGuerin therapy: correlation to clinical outcome. J Clin Oncol 1996; 14: 2646-52
47. Caliskan M. Turkeri LN, Mansuroglu B et al. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 1997; 79: 373-7
48. Lebret T. Becette V, Baragelatta M et al. Correlation between p53 over expression and response to Bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998: 159: 788-91
49. Underwood MA. Reeves J. Smith G et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996; 77: 659-66
50. Tetu B. Fradet Y. Allard P. Veilleux C. Roberge N. Bernard P. Prevalence and clinical significance of HER/2neu. p53 and Rb expression in primary superficial bladder cancer. J Urol 1996: 155: 1784-8
51. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. bit I Cancer 1993: 53: 365-70
52. Gardiner RA. Walsh MU, Alien V et al. Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression. Br }Urol 1994: 73: 526-32
53. Schmitz-Drager BJ. International study on the standardisation of p53 immunohistochemistry for the prognosis of bladder cancer. International study initiative on bladder cancer. In preparation
54. Lianes P, Orlow I. Zhang ZF et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1 325-30
55. Barbareschi M. Girlando S. Fellin G. Graffer U. Luciani L. Dalla Palma P. Expression of mdm-2 and p55 protein in transitional cell carcinoma. Urol Res 1995: 22: 349-52
56. Schmitz-Drager BJ, Kushima M. Goebell P et 1. p53 and Mdm2 in the development and progression of bladder cancer. Eur Urol 1997; 32: 487-93
57. Keegan PE. Griffiths TRL. Marsh C. Lunec ), Robinson MC. Neal DE. MDM2 and p5 3 immunoreactivity: Independent predictors of stage progression in pTl bladder cancer (TCC). Br J Urol 1998: 81 (Suppl 4): 16. P14
58. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunée J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996; 2: 912-7
59. Wurl P. Meye A, Berger D et al. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas. Diagn Mol Pathol 1997; 6: 249-54
60. Lacombe L, Orlow I, Silver D et al. Analysis of p21WAFl/CIPl in primary bladder tumors. Oncol Res 1996; 8: 409-14
61. Malkowicz SB, Tomaszewski JE. Linnenbach AJ, Cangiano TA, Maruta Y, McGarvey TW. Novel p21WAFl/CIPl mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996; 13: 1831-7
62. Braithwaite KL, Mellon JK, Neal DE. WAF1 expression in transitional cell carcinoma (TCC) of the bladder: Inverse relationship to p53 accumulation and association with good prognosis. Abstract no. 3534. American Association for Cancer Research, 1997
63. Lee CC, Yamamoto S, Morimura K et al. Significance of cyclin Dl overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997; 79: 780-9
64. Bringuier PP, Tamimi Y. Schuuring E, Schalken J. Expression of cyclin Dl and EMS1 in bladder tumours; relationship with chromosome Ilql3 amplification. Oncogene 1996; 12: 1747-53
65. Shin KY, Kong G, Kirn WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D l correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997; 75: 1788-92
66. Wright C, Thomas D, Mellon K, Neal DE, Hörne CH. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. Br JUrol 1995; 75: 173-9
67. Cordon-Cardo C, Zhang ZF, Dalbagni G et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21
68. Pollack A, Czerniak B, Zagars GK et al. Retinoblastoma protein expression and radiation response in muscleinvasive bladder cancer. Int J Radiât Oncol Biol Phys 1997; 39: 687-95
69. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. JPathol 1994; 173: 333-9
70. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155: 316-20
71. Gazzaniga P, Gradilone A, Vercillo R et al. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996; 69: 100-4
72. Grossfeld GD, Ginsberg DA, Stein JP et al Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 219-27
73. Raitanen MP, Tammela TL, Kallioinen M, Isola J. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997; 157: 1250-3
74. Click SH, Howell LP, White RW. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996; 155: 1754-7
75. Nakopoulou L. Constantinides C, Papandropoulos J et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995; 46: 334-40
76. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2. p53) expression and long-term prognosis. Br J Cancer 1994; 69: 1120-5
77. Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE. P53 expression, ploidy and progression in pTl transitional cell carcinoma of the bladder. Br) Urol 1994; 73: 533-7